Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Shedding Light On Esophageal Disease
Canadian Light (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron"s infrared microscope to identify tissue afflicted with a condition known as Barrett"s Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. The finding is published in the June, 2009 issue of the Royal Society of Chemistry journal, The Analyst.
generic viagra online
House Panel Passes Protection For Drug Makers
The House Energy and Commerce Committee passed an amendment to their broad health reform bill giving drug makers 12 years of exclusive rights to market new biologic drugs, "a setback" to the administration and consumer advocates who hoped to make generic drugs more widely available, the Wall Street Journal reports. The panel voted 47-11 on the measure, which "would also allow "evergreening," the practice by pharmaceutical companies of making minimal adjustments to their drugs, such as creating extended-release versions, as a way to lengthen their monopoly."
News of the day
Research Assesses The Benefits Of Different Ways Of Treating Tooth Decay In Children
New research commissioned by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme will assess the benefits of different methods of managing tooth decay in children"s teeth. Dental decay is one of the most common childhood diseases, with over 40 per cent of children in the UK already experiencing obvious decay in their primary (baby) teeth by five years of age, and this statistic has remained largely unchanged for the past 20 years.
Diagnostics

FDA Approval For Cetirizine Hydrochloride Tablets (OTC) ANDA - Hay Fever And Other Respiratory Allergies

Taro Pharmaceutical Industries Ltd. reported that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride tablets (OTC), 5 mg and 10 mg ("Cetirizine Tablets"). The product will be marketed by Taro"s U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc. Taro"s Cetirizine Tablets are bioequivalent to McNeil Consumer Healthcare"s Zyrtec® Allergy Tablets, 5 mg and 10 mg and Zyrtec® Hives Relief Tablets, 5 mg and 10 mg. Taro previously received approval for cetirizine hydrochloride oral solution in April 2008. Cetirizine Tablets are a nonprescription drug approved for the temporary relief of symptoms due to hay fever or other respiratory allergies (sneezing; runny nose; itchy, watery eyes; itchy throat or nose) in adults and children 2 years of age and older. Cetirizine Tablets are also approved for the relief of itching due to hives in adults and children 6 years of age and older. According to industry s, annual U.S. sales of this product are approximately $350 million. Taro is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. Taro Pharmaceutical Industries Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009